Working… Menu
Trial record 4 of 42 for:    FROVATRIPTAN

A Research Study To Evaluate If Frovatriptan Is Safe And Effective In Preventing Migraine Headache After Fasting

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00440232
Recruitment Status : Completed
First Posted : February 26, 2007
Results First Posted : November 18, 2010
Last Update Posted : May 26, 2011
Information provided by:
Thomas Jefferson University

Brief Summary:
We are testing the hypothesis that subjects in the treatment group will experience fewer fasting induced headaches as compared to those in the placebo group.In our clinical experience, we estimate that approximately 25% of our headache population experiences fasting-induced migraine or hunger-induced migraine. With a given migraine incidence of 28 million in the United States alone, we estimate that approximately 7 million will experience hunger as a migraine trigger. If an individual has a known migraine trigger, then there are a variety of ways to modify care in order to address that trigger. The simplest is to avoid that trigger or preemptively treat that trigger. Frovatriptan has good evidence for daily use for a short time to help prevent menstrually related migraines. A short course of treatment can often avoid the initiation of the migraine and improve quality of life. Knowing that a longer acting triptan, such as frovatriptan, has demonstrated capability at suppressing headache through a known trigger, suggests the need to study this with fasting induced migraines, as well.

Condition or disease Intervention/treatment Phase
Migraine Drug: Frovatriptan Drug: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 74 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Pilot Trial Examining the Safety and Efficacy of Frovatriptan as a Preemptive Treatment for Fasting-Induced Migraine Headache
Study Start Date : July 2007
Actual Primary Completion Date : March 2009
Actual Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Headache Migraine

Arm Intervention/treatment
Experimental: Frovatriptan
5.0 mg of Frovatriptan given as single dose
Drug: Frovatriptan
Frovatriptan 5.0 mg orally one time at the start of the 20 hour fast
Other Name: Frova

Placebo Comparator: placebo Drug: Placebo
Inert tab identical in appearance to Frovatriptan

Primary Outcome Measures :
  1. Incidence of Fasting-induced Headache of Any Intensity [ Time Frame: 20 hours ]
    Incidence of fasting-induced headache of any intensity occurring at greater than 4 hours, but within 20 hours after onset of fasting

Secondary Outcome Measures :
  1. Time to Development of Headache of Any Intensity [ Time Frame: 20 hours ]
    Time to development of headache of any intensity in the 2 treatment arms

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female subjects between the ages of 18 and 65, inclusive
  • Subjects diagnosed with episodic migraine, with or without aura according to IHS criteria for at least one-year prior to screening
  • Subjects who experience between 1 and 6 migraine attacks per month inclusive (during the previous 6 months) with no more than 15 days of headache per month.
  • Subject reports hunger or fasting as a known trigger for migraine
  • Subject is using or agrees to use for the duration of participation a medically acceptable form of contraception (as determined by investigator), if female of child-bearing potential
  • Subjects who are able to understand and comply with all study procedures.
  • Subject is willing to complete one 20-hour fast, starting between 5:00 and 8:00 P.M., with no food or drink (except water needed to take routine medication)
  • Subject provides written informed consent prior to any screening procedures being conducted
  • If subject is taking a preventive migraine medication for migraine or any other reason, that medication must have been a stable dose for at least 4 weeks prior to screening, and must remain stable throughout the duration of the study.


  • Pregnant and/or lactating women
  • Subjects who have a history of clinically relevant allergy to frovatriptan or like compounds
  • Subjects who, in the investigators opinion, have a history or have evidence of any other medical or psychiatric condition that would expose them to an increased risk of a significant adverse event or would interfere with the assessments of efficacy and tolerability during this trial
  • Subjects who have participated in an investigational drug trial in the 30 days prior to the screening visit
  • Subjects who currently have or have a history of significant cerebrovascular disease including basilar or hemiplegic migraine
  • Subjects who have a history of non-response to triptans, as determined by investigator
  • Subjects with uncontrolled hypertension
  • Subjects with diabetes mellitus who require insulin or oral anti-hyperglycemic agents will be excluded. (Subjects with Type II diabetes who are well controlled with diet and exercise alone may be included.)
  • Subjects who currently have or who have a history of ischemia and/or vasospastic coronary artery disease
  • Subjects who, in the investigators opinion, have significant risk factors of coronary artery disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00440232

Layout table for location information
United States, Pennsylvania
Jefferson Headache Center
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Thomas Jefferson University
Layout table for investigator information
Principal Investigator: Stephen D. Silberstein, M.D. Thomas Jefferson University

Layout table for additonal information
Responsible Party: Stephen D. Silberstein, M.D., Jefferson Headache Center, Thomas Jefferson University Identifier: NCT00440232     History of Changes
Other Study ID Numbers: SDS/FHA-FRV/ 01
First Posted: February 26, 2007    Key Record Dates
Results First Posted: November 18, 2010
Last Update Posted: May 26, 2011
Last Verified: May 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs